SynAct Pharma AB (publ) (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as “pro-resolution”, today announced its attendance and presentations at multiple upcoming conferences in September and October 2026.
BioStock Investing in Life Science 2026, September 22, Stockholm, Sweden
Format: Company presentation
Presenting: Jeppe Øvlesen, Chief Executive Officer
Time: Tuesday, September 22, 11:55am CEST
Location: Main session
LSX Congress USA 2026, September 22-24, Boston, USA
Format: Panel discussion
Panel: From Seed to Scale: CEO Perspectives on Building Resilient Biotech Companies in Uncertain Markets
Panel Member: Mads Bjerregaard, Chief Business Officer
Time: Tuesday, September 22, 2026, 2:30pm - 3:00pm ET (Eastern Time, GMT-05:00)
Location: Biotech CEO Forum (Room 303)
Format: Company presentation
Presenting: Mads Bjerregaard, Chief Business Officer
Time: Wednesday, September 23, 4:30pm - 4:45pm ET
Location: Growth Showcase (Exhibition Hall)
Management will also be available to meet with investors and partners at the following conferences:
European MidCap Event 2026, September 30-October 1, Paris, France
Sachs Associates 26th Annual Biotech in Europe Forum, October 7- 8, Basel, Switzerland
Bio Japan, October 7-8, Yokohama, Japan